SVRA
Savara Inc.
$4.92
+$0.25(+5.35%)
70
Overall
50
Value
91
Tech
--
Quality
Market Cap
$686.16M
Volume
2.40M
52W Range
$1.89 - $4.91
Target Price
$10.19
Company Overview
| Mkt Cap | $686.16M | Price | $4.92 |
| Volume | 2.40M | Change | +5.35% |
| P/E Ratio | -7.2 | Open | $4.66 |
| Revenue | -- | Prev Close | $4.67 |
| Net Income | $-95.9M | 52W Range | $1.89 - $4.91 |
| Div Yield | N/A | Target | $10.19 |
| Overall | 70 | Value | 50 |
| Quality | -- | Technical | 91 |
No chart data available
About Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest News
Savara Inc. Reports Q3 2025 Financial Results
TipRanks Auto-Generated Newsdesk•6 days ago
Savara Hit with Class Action Over Molbreevi Misrepresentations
Sheryl Sheth•20 days ago
Savara Announces $75M Royalty Funding Agreement
TipRanks Auto-Generated Newsdesk•25 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SVRA | $4.92 | +5.4% | 2.40M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |